A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)

Trial Profile

A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Dexamethasone; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-189; MK-3475-189/KEYNOTE-189
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 05 Jun 2018 Results assessing health-related quality of life, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 21 May 2018 Planned End Date changed from 31 Jan 2020 to 15 Apr 2019.
    • 16 May 2018 According to an Eli Lilly media release, data from this trial will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top